KlegermanAlport syndrome: an interview with Dr Paul Grint, CMO, RegulusDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix ‘We anticipate the final results of the trial, which are anticipated in the second fifty % of 2011 with belief that the combination of aflibercept and FOLFIRI has the potential to benefit patients with this difficult-to-deal with disease,’ stated Tal Zaks, Head of Development, Global Oncology Division, sanofi-aventis.. Aflibercept Stage 3 VELOUR medical trial for mCRC to continue to completion Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR medical trial of aflibercept in individuals with metastatic colorectal tumor will continue steadily to completion as prepared, with no modifications because of efficacy or safety worries.Locally advanced prostate cancer is cancer which has spread outside but near the prostate gland. Unlike slower growing tumors, locally advanced prostate tumor is an aggressive malignancy that is susceptible to metastasize and trigger malignancy deaths. Hormone therapy lowers or blocks the degrees of testosterone and additional androgens that feed prostate cancers tumors. Two landmark medical trials show that radiation plus hormone therapy generates a big and significant improvement in survival in young men in accordance with hormone therapy by itself, but until now there’s been no comparable study on treatment for older men with advanced prostate cancers. Addressing this question for the very first time, Penn's research team compared the combination of radiation in addition hormone therapy versus hormone therapy alone among 31, 541 men with prostate tumor ranging in age from 65 years to 85 years.